BLINK THERAPEUTICS LIMITED - Accounts 2014


ABBREVIATED ACCOUNTS


FOR THE YEAR ENDED 31/03/2014

















INDEX TO THE ACCOUNTS




Abbreviated Balance Sheet		2

Notes to the Abbreviated Accounts		3



The company's registered number is 07596557


Registered Number: 07596557

BALANCE SHEET AT 31/03/2014

			2014		2013
	Notes		£		£

FIXED ASSETS
Tangible assets	2		16,512		-

CURRENT ASSETS
Debtors (amounts falling due within one year)	3	75,106		46,949
Cash at bank and in hand		587,540		912,835
		662,646		959,784
CREDITORS: Amounts falling due within one year		410,128		287,250
NET CURRENT ASSETS			252,518		672,534
TOTAL ASSETS LESS CURRENT LIABILITIES			269,030		672,534

CAPITAL AND RESERVES

Called up share capital	4		20		20
Other reserves			2,134,238		1,634,238
Profit and loss account			(1,865,228)		(961,724)
SHAREHOLDERS' FUNDS			269,030		672,534

For the year ending 31/03/2014 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the board on 30/05/2014 and signed on their behalf by




DR LJ NISBET
Director

1. ACCOUNTING POLICIES




1a. Basis Of Accounting
The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).




1b. Going Concern
These financial statements have been prepared on the going concern basis. The lead investor has confirmed that it is their intention to continue funding the research carried out by the company, provided that the company continues to advance the research projects. The directors are confident that the research targets will all be achieved and that the investor will continue with the financial support that has been in place since the company was formed in 2011.




1c. Tangible Assets
Fixed assets are shown at historical cost.
Depreciation is provided, after taking account of any grants receivable, at the following annual rates in order to write off each asset over its estimated useful life.
50%




1d. Foreign Currency
Transactions in foreign currency are translated at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the exchange rate ruling at that date. Foreign exchange gains and losses are recognised in the income statement. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.




3. DEBTORS	2014	2013
	£	£

Amounts falling due within one year:
Other debtors	75,106	46,949
	75,106	46,949




4. SHARE CAPITAL	2014	2013
	£	£
Allotted, issued and fully paid:
2000 Ordinary shares of £0.01 each	20	20
	20	20




5. RELATED PARTY TRANSACTIONS
Fees of £12,109 were paid to Haversian Limited, a company controlled by Dr M Moore. Fees of £12,000 were paid to Vivanova Limited, a company controlled by Dr L Nisbet. Fees of £9,000 were paid to Dr M Owen. Fees of £7,500 were paid to Dr R Mehta.